XML 55 R29.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Segment Information (Tables) | 6 Months Ended
--- | ---
Dec. 31, 2018
Segment Reporting [Abstract] |
Segment Information | 14. Segment Information Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities. Revenue Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers to support the development, marketing and distribution of specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. The following table presents revenue for each reportable segment and Corporate:
| Three Months Ended December 31,
(in millions) | 2018 |  | 2017
Pharmaceutical | $ | 33,740 |  |  | $ | 31,146 |
Medical | 4,006 |  |  | 4,044 |
Total segment revenue | 37,746 |  |  | 35,190 |
Corporate (1) | (6 | ) |  | (4 | )
Total revenue | $ | 37,740 |  |  | $ | 35,186 |
| Six Months Ended December 31,
(in millions) | 2018 |  | 2017
Pharmaceutical | $ | 65,155 |  |  | $ | 60,066 |
Medical | 7,807 |  |  | 7,768 |
Total segment revenue | 72,962 |  |  | 67,834 |
Corporate (1) | (9 | ) |  | (7 | )
Total revenue | $ | 72,953 |  |  | $ | 67,827 |
(1) | Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
The following table presents disaggregated revenue within our two reportable segments:
| Three months ended December 31, 2018 |  | Six months ended December 31, 2018
(in millions) |  |  |
Pharmaceutical distribution and specialty | $ | 33,534 |  |  | $ | 64,742 |
Nuclear and Precision Health Solutions (1) | 206 |  |  | 413 |
Pharmaceutical segment revenue | 33,740 |  |  | 65,155 |
Medical distribution and products (2) | 3,527 |  |  | 6,907 |
Cardinal Health At Home | 479 |  |  | 900 |
Medical segment revenue | 4,006 |  |  | 7,807 |
Total segment revenue | 37,746 |  |  | 72,962 |
Corporate (3) | (6 | ) |  | (9 | )
Total revenue | $ | 37,740 |  |  | $ | 72,953 |
(1) | Our Nuclear and Precision Health Solutions division was formerly referred to as our Nuclear Pharmacy Services division.
(2) | Comprised of all Medical segment businesses except for Cardinal Health At Home division.
(3) | Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
The following table presents revenue by geographic area:
| Three months ended December 31, 2018 |  | Six months ended December 31, 2018
(in millions) |  |  |
United States | $ | 36,716 |  |  | $ | 70,960 |
International | 1,030 |  |  | 2,002 |
Total segment revenue | 37,746 |  |  | 72,962 |
Corporate (1) | (6 | ) |  | (9 | )
Total revenue | $ | 37,740 |  |  | $ | 72,953 |
(1) | Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment SG&A expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, legal and compliance. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit. We do not allocate the following items to our segments: last-in first-out, or ("LIFO"), inventory charges/(credits); restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; state opioid assessment related to prior fiscal years; other (income)/expense, net; interest expense, net; loss on extinguishment of debt; and provision for/(benefit from) income taxes. In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $12 million and $6 million for the three months ended December 31, 2018 and 2017, respectively, and $19 million and $11 million for the six months ended December 31, 2018 and 2017, respectively. In connection with the naviHealth divestiture discussed in Note 4, we recognized a pre-tax gain of $508 million during the six months ended December 31, 2018, which was retained at Corporate. The following table presents segment profit by reportable segment and Corporate:
| Three Months Ended December 31,
(in millions) | 2018 |  | 2017
Pharmaceutical | $ | 443 |  |  | $ | 514 |
Medical | 188 |  |  | 220 |
Total segment profit | 631 |  |  | 734 |
Corporate | (127 | ) |  | (335 | )
Total operating earnings | $ | 504 |  |  | $ | 399 |
| Six Months Ended December 31,
(in millions) | 2018 |  | 2017
Pharmaceutical | $ | 851 |  |  | $ | 981 |
Medical | 323 |  |  | 348 |
Total segment profit | 1,174 |  |  | 1,329 |
Corporate | 146 |  |  | (668 | )
Total operating earnings | $ | 1,320 |  |  | $ | 661 |
The following table presents total assets for each reportable segment and Corporate at:
(in millions) | December 31, 2018 |  | June 30, 2018
Pharmaceutical | $ | 22,101 |  |  | $ | 21,421 |
Medical | 15,697 |  |  | 16,066 |
Corporate | 2,664 |  |  | 2,464 |
Total assets | $ | 40,462 |  |  | $ | 39,951 |
Revenue by Reportable Segment | The following table presents revenue for each reportable segment and Corporate:
| Three Months Ended December 31,
(in millions) | 2018 |  | 2017
Pharmaceutical | $ | 33,740 |  |  | $ | 31,146 |
Medical | 4,006 |  |  | 4,044 |
Total segment revenue | 37,746 |  |  | 35,190 |
Corporate (1) | (6 | ) |  | (4 | )
Total revenue | $ | 37,740 |  |  | $ | 35,186 |
| Six Months Ended December 31,
(in millions) | 2018 |  | 2017
Pharmaceutical | $ | 65,155 |  |  | $ | 60,066 |
Medical | 7,807 |  |  | 7,768 |
Total segment revenue | 72,962 |  |  | 67,834 |
Corporate (1) | (9 | ) |  | (7 | )
Total revenue | $ | 72,953 |  |  | $ | 67,827 |
(1) | Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Disaggregation of Revenue [Table Text Block] | The following table presents disaggregated revenue within our two reportable segments:
| Three months ended December 31, 2018 |  | Six months ended December 31, 2018
(in millions) |  |  |
Pharmaceutical distribution and specialty | $ | 33,534 |  |  | $ | 64,742 |
Nuclear and Precision Health Solutions (1) | 206 |  |  | 413 |
Pharmaceutical segment revenue | 33,740 |  |  | 65,155 |
Medical distribution and products (2) | 3,527 |  |  | 6,907 |
Cardinal Health At Home | 479 |  |  | 900 |
Medical segment revenue | 4,006 |  |  | 7,807 |
Total segment revenue | 37,746 |  |  | 72,962 |
Corporate (3) | (6 | ) |  | (9 | )
Total revenue | $ | 37,740 |  |  | $ | 72,953 |
(1) | Our Nuclear and Precision Health Solutions division was formerly referred to as our Nuclear Pharmacy Services division.
(2) | Comprised of all Medical segment businesses except for Cardinal Health At Home division.
(3) | Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Revenue from External Customers by Geographic Areas [Table Text Block] | The following table presents revenue by geographic area:
| Three months ended December 31, 2018 |  | Six months ended December 31, 2018
(in millions) |  |  |
United States | $ | 36,716 |  |  | $ | 70,960 |
International | 1,030 |  |  | 2,002 |
Total segment revenue | 37,746 |  |  | 72,962 |
Corporate (1) | (6 | ) |  | (9 | )
Total revenue | $ | 37,740 |  |  | $ | 72,953 |
(1) | Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit by Reportable Segment | The following table presents segment profit by reportable segment and Corporate:
| Three Months Ended December 31,
(in millions) | 2018 |  | 2017
Pharmaceutical | $ | 443 |  |  | $ | 514 |
Medical | 188 |  |  | 220 |
Total segment profit | 631 |  |  | 734 |
Corporate | (127 | ) |  | (335 | )
Total operating earnings | $ | 504 |  |  | $ | 399 |
| Six Months Ended December 31,
(in millions) | 2018 |  | 2017
Pharmaceutical | $ | 851 |  |  | $ | 981 |
Medical | 323 |  |  | 348 |
Total segment profit | 1,174 |  |  | 1,329 |
Corporate | 146 |  |  | (668 | )
Total operating earnings | $ | 1,320 |  |  | $ | 661 |
Assets by Reportable Segment | The following table presents total assets for each reportable segment and Corporate at:
(in millions) | December 31, 2018 |  | June 30, 2018
Pharmaceutical | $ | 22,101 |  |  | $ | 21,421 |
Medical | 15,697 |  |  | 16,066 |
Corporate | 2,664 |  |  | 2,464 |
Total assets | $ | 40,462 |  |  | $ | 39,951 |

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599 + Details
Name: | us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph a -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration